Company / Cost of Revenue
Harmony Biosciences Holdings, Inc. Cost of Revenue History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$198.3M
FY2025
5-year range
$1.6M / $198.3M
FY2021-FY2025
Trend
+26.5%
vs FY2024
Sector context
#35 of 85
Health Care
What the data says
At $198M, Harmony Biosciences Holdings, Inc.'s cost of revenue ranks #51 of 85 in the Health Care sector. Cost of Revenue has increased for 4 consecutive years, from $2M in FY2021 to $198M in FY2025.
Based on SEC 10-K filings.
$198M in FY2025 with a 5-year CAGR of +163.0%.
Increased from $121M to $198M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +33.4%
- 5-Year CAGR
- +163.0%
- 10-Year CAGR
- -
Sector benchmark
#51 of 85 in Health CareTop 59% of 85This company $198.3M Sector average $2.0B
▼
-90.0% below sector average
Key checks
Key Insights
- Harmony Biosciences Holdings, Inc.'s cost of revenue has grown for 4 consecutive years.
- 5-year CAGR of +163.0%, indicating consistent growth.
- In FY2025, cost of revenue increased 26.5% year-over-year.
- Ranks #35 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $198.3M | +26.5% |
| FY2024 | $156.8M | +29.3% |
| FY2023 | $121.2M | +45.2% |
| FY2022 | $83.5M | +5193.7% |
| FY2021 | $1.6M | +0.0% |
| FY2020 | $1.6M | +0.0% |
| FY2019 | $1.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026